Harry Dolstra

Harry Dolstra

Auto-generated profile, based on publicly available information

Harry Dolstra

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
CMCharlotte M. Mousset
Charlotte M. Mousset
WHWillemijn Hobo
Willemijn Hobo
RWRob Woestenenk
Rob Woestenenk
FPFrank Preijers
Frank Preijers
HDHarry Dolstra
Harry Dolstra
AWAnniek B. van der Waart
Anniek B. van der Waart

1 August 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HDHarry Dolstra
Harry Dolstra
MRMieke W.H. Roeven
Mieke W.H. Roeven
JSJan Spanholtz
Jan Spanholtz
BHBasav N. Hangalapura
Basav N. Hangalapura
MTMarleen Tordoir
Marleen Tordoir
NSNicolaas Schaap
Nicolaas Schaap
Purpose: Older acute myeloid leukemia (AML) patients have a poor prognosis; therefore, novel therapies are needed. Allogeneic natural killer (NK) cells have been adoptively transferred with promising clinical results. Here, we report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units. Experimental Design: Ten older AML patients in morphologic complete remission received an escalating HSPC-NK cell dose (between 3 and 30 × 106/kg body weight) after lymphodepleting chemotherapy without cytokine boosting. Results: HSPC-NK cell products contained a median of 75% highly activated NK cells, with <1 × 104 T cells/kg and <3 × 105 B cells/kg body weight. HSPC-NK cells were well tolerated, and neither graft-versus-host disease nor toxicity was observed. Despite no cytokine boosting being given, transient HSPC-NK cell persistence was clearly found in peripheral blood up to 21% until day 8, which was accompanied by augmented IL15 plasma levels. Moreover, donor chimerism up to 3.5% was found in bone marrow. Interestingly, in vivo HSPC-NK cell maturation was observed, indicated by the rapid acquisition of CD16 and KIR expression, while expression of most activating receptors was sustained. Notably, 2 of 4 patients with minimal residual disease (MRD) in bone marrow before infusion became MRD negative (<0.1%), which lasted for 6 months. Conclusions: These findings indicate that HSPC-NK cell adoptive transfer is a promising, potential “off-the-shelf” translational immunotherapy approach in AML. Clin Cancer Res; 23(15); 4107–18. ©2017 AACR.

27 November 2014 in Blood
Verified
Journal Article
Open access
PDF file
AWAnniek B. van der Waart
Anniek B. van der Waart
NWNoortje M. P. van de Weem
Noortje M. P. van de Weem
FMFrans Maas
Frans Maas
CKCynthia S. M. Kramer
Cynthia S. M. Kramer
MKMichel G. D. Kester
Michel G. D. Kester
HDHarry Dolstra
Harry Dolstra
Effective T-cell therapy against cancer is dependent on the formation of long-lived, stem cell–like T cells with the ability to self-renew and differentiate into potent effector cells. Here, we investigated the in vivo existence of stem cell–like antigen-specific T cells in allogeneic stem cell transplantation (allo-SCT) patients and their ex vivo generation for additive treatment posttransplant. Early after allo-SCT, CD8+ stem cell memory T cells targeting minor histocompatibility antigens (MiHAs) expressed by recipient tumor cells were not detectable, emphasizing the need for improved additive MiHA-specific T-cell therapy. Importantly, MiHA-specific CD8+ T cells with an early CCR7+CD62L+CD45RO+CD27+CD28+CD95+ memory-like phenotype and gene signature could be expanded from naive precursors by inhibiting Akt signaling during ex vivo priming and expansion. This resulted in a MiHA-specific CD8+ T-cell population containing a high proportion of stem cell–like T cells compared with terminal differentiated effector T cells in control cultures. Importantly, these Akt-inhibited MiHA-specific CD8+ T cells showed a superior expansion capacity in vitro and in immunodeficient mice and induced a superior antitumor effect in intrafemural multiple myeloma–bearing mice. These findings provide a rationale for clinical exploitation of ex vivo–generated Akt-inhibited MiHA-specific CD8+ T cells in additive immunotherapy to prevent or treat relapse in allo-SCT patients.

1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
RMRalph Ja Maas
Ralph Ja Maas
JEJanneke Hoogstad-van Evert
Janneke Hoogstad-van Evert
JMJolien Mr Van der Meer
Jolien Mr Van der Meer
VMVera Mekers
Vera Mekers
SRSomayeh Rezaeifard
Somayeh Rezaeifard
HDHarry Dolstra
Harry Dolstra
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively correlate with patient survival. Among these infiltrating lymphocytes are natural killer (NK) cells, key players involved in tumor targeting, initiated by signaling via activating and inhibitory receptors. Here, we investigated the role of the DNAM-1/TIGIT/CD96 axis in the anti-tumor response of NK cells toward OC. Ascites-derived NK cells from advanced OC patients showed lower expression of activating receptor DNAM-1 compared to healthy donor peripheral blood NK cells, while inhibitory receptor TIGIT and CD96 expression was equal or higher, respectively. This shift to a more inhibitory phenotype could also be induced in vitro by co-culturing healthy donor NK cells with OC tumor spheroids, and in vivo on intraperitoneally infused NK cells in SKOV-3 OC bearing NOD/SCID-IL2Rγnull (NSG) mice. Interestingly, TIGIT blockade enhanced degranulation and interferon gamma (IFNγ) production of healthy donor CD56dim NK cells in response to OC tumor cells, especially when DNAM-1/CD155 interactions were in place. Importantly, TIGIT blockade boosted functional responsiveness of CD56dim NK cells of OC patients with a baseline reactivity against SKOV-3 cells. Overall, our data show for the first time that checkpoint molecules TIGIT/DNAM-1/CD96 play an important role in NK cell responsiveness against OC, and provides rationale for incorporating TIGIT interference in NK cell-based immunotherapy in OC patients.

1 August 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
DBDirk van Den Brand
Dirk van Den Brand
MGMark A.J. Gorris
Mark A.J. Gorris
AAAlexander H. van Asbeck
Alexander H. van Asbeck
EPEmma Palmen
Emma Palmen
IEInge Ebisch
Inge Ebisch
RBRoland Brock
Roland Brock

1 July 2020 in Cytotherapy
Verified
Journal Article
Open access
RHRenske M.T. Ten Ham
Renske M.T. Ten Ham
AHAnke M. Hövels
Anke M. Hövels
JHJarno Hoekman
Jarno Hoekman
GFGeert W.J. Frederix
Geert W.J. Frederix
HLHubert G.M. Leufkens
Hubert G.M. Leufkens
MHMarcel H.N. Hoefnagel
Marcel H.N. Hoefnagel
Recent technical and clinical advances with cell-based therapies (CBTs) hold great promise in the treatment of patients with rare diseases and those with high unmet medical need. Currently the majority of CBTs are developed and manufactured in specialized academic facilities. Due to small scale, unique characteristics and specific supply chain, CBT manufacturing is considered costly compared to more conventional medicinal products. As a result, biomedical researchers and clinicians are increasingly faced with cost considerations in CBT development. The objective of this research was to develop a costing framework and methodology for academic and other small-scale facilities that manufacture cell-based therapies. We conducted an international multi-center costing study in four facilities in Europe using eight CBTs as case studies. This study includes costs from cell or tissue procurement to release of final product for clinical use. First, via interviews with research scientists, clinicians, biomedical scientists, pharmacists and technicians, we designed a high-level costing framework. Next, we developed a more detailed uniform methodology to allocate cost items. Costs were divided into steps (tissue procurement, manufacturing and fill-finish). The steps were each subdivided into cost categories (materials, equipment, personnel and facility), and each category was broken down into facility running (fixed) costs and operational (variable) costs. The methodology was tested via the case studies and validated in developer interviews. Costs are expressed in 2018 euros (€). The framework and methodology were applicable across facilities and proved sensitive to differences in product and facility characteristics. Case study cost estimates ranged between €23 033 and €190 799 Euros per batch, with batch yield varying between 1 and 88 doses. The cost estimations revealed hidden costs to developers and provided insights into cost drivers to help design manufacturing best practices. This framework and methodology provide step-by-step guidance to estimate manufacturing costs specifically for cell-based therapies manufactured in academic and other small-scale enterprises. The framework and methodology can be used to inform and plan cost-conscious strategies for CBTs.